Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CUDC-907 in Pediatric Relapsed/Refractory Solid Tumors, CNS Tumors, or Lymphoma
NCT02909777Phase 1Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Oct 2016
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fimepinostat in solid tumor, central nervous system tumor, lymphoma and 1 more, sponsored by Dana-Farber Cancer Institute. Primary endpoint: Dose Limiting Toxicity at 2 years. Started Oct 2016; status: completed.
02
Drugs
fimepinostat
03
Conditions
solid tumorcentral nervous system tumorlymphomaneuroblastoma
Beyond the preview
Go deeper on NCT02909777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02909777.